DCPH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
DCPH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Deciphera Pharmaceuticals's enterprise value is $1,950.7 Mil. Deciphera Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $174.9 Mil. Therefore, Deciphera Pharmaceuticals's EV-to-Revenue for today is 11.15.
The historical rank and industry rank for Deciphera Pharmaceuticals's EV-to-Revenue or its related term are showing as below:
During the past 9 years, the highest EV-to-Revenue of Deciphera Pharmaceuticals was 360.40. The lowest was 1.61. And the median was 9.14.
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
As of today (2024-05-14), Deciphera Pharmaceuticals's stock price is $25.44. Deciphera Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $2.03. Therefore, Deciphera Pharmaceuticals's PS Ratio for today is 12.54.
The historical data trend for Deciphera Pharmaceuticals's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Deciphera Pharmaceuticals Annual Data | |||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||||||
EV-to-Revenue | Get a 7-Day Free Trial | 106.03 | 65.73 | 3.30 | 6.07 | 6.23 |
Deciphera Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
EV-to-Revenue | Get a 7-Day Free Trial | 6.09 | 5.61 | 4.66 | 6.23 | 5.97 |
For the Drug Manufacturers - Specialty & Generic subindustry, Deciphera Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Deciphera Pharmaceuticals's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Deciphera Pharmaceuticals's EV-to-Revenue falls into.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
Deciphera Pharmaceuticals's EV-to-Revenue for today is calculated as:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 1950.715 | / | 174.91 | |
= | 11.15 |
Deciphera Pharmaceuticals's current Enterprise Value is $1,950.7 Mil.
Deciphera Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $174.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Deciphera Pharmaceuticals (NAS:DCPH) EV-to-Revenue Explanation
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
Deciphera Pharmaceuticals's PS Ratiofor today is calculated as:
PS Ratio | = | Share Price (Today) | / | Revenue per Share (TTM) |
= | 25.44 | / | 2.028 | |
= | 12.54 |
Deciphera Pharmaceuticals's share price for today is $25.44.
Deciphera Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.03.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Deciphera Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Jama Pitman | officer: SVP, Regulatory & Quality | C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451 |
Daniel C. Martin | officer: Chief Commercial Officer | C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451 |
Thomas Patrick Kelly | officer: Chief Financial Officer | C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451 |
Matthew L Sherman | officer: EVP & Chief Medical Officer | C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451 |
Steven L. Hoerter | director | C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451 |
Dashyant Dhanak | officer: EVP & Chief Scientific Officer | C/O INCYTE CORPORATION, 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803 |
Daniel Lee Flynn | officer: Chief Scientific Officer | C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451 |
Franklin Stuart Friedman | director | C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451 |
Dennis Leo Walsh | director | C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451 |
Brightstar Associates Llc | 10 percent owner | 1020 CENTRAL STREET, KANSAS CITY MO 64105 |
James Arthur Bristol | director | C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451 |
Michael Douglas Taylor | director, officer: See Remarks | C/O DECIPHERA PHARMACEUTICALS, LLC, 500 TOTTEN POND ROAD, WALTHAM MA 02451 |
Patricia L Allen | director | C/O DECIPHERA PHARMACEUTICALS, INC, 200 SMITH STREET, WALTHAM MA 02451 |
Christopher John Morl | officer: Chief Business Officer | C/O DECIPHERA PHARMACEUTICALS, LLC, 500 TOTTEN POND ROAD, WALTHAM MA 02451 |
Ron Squarer | director | C/O ADC THERAPEUTICS SA, BIOPOLE, ROUTE DE LA CORNICHE 3B, EPALINGES V8 1066 |
From GuruFocus
By Business Wire Business Wire • 01-31-2023
By GuruFocus Research • 11-01-2023
By Business Wire • 09-15-2023
By GuruFocus Research • 10-05-2023
By Business Wire • 08-02-2023
By GuruFocus Research • 10-31-2023
By GuruFocus Research • 12-28-2023
By Business Wire Business Wire • 01-24-2023
By Business Wire • 01-08-2024
By GuruFocus Research • 09-22-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.